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Aim: Osteopontin (OPN) has been investigated as a biomarker for cancer and nonmalignant dis-
eases during the last decades. Data about OPN as a potential biomarker in childhood diseases are
still sparse, and reference values are not available in children. We aimed to establish reference
values for children from birth to young adulthood and evaluate whether there are age-, gender-,
and weight-specific differences.
Method: Umbilical cord blood and blood plasma samples of 117 children were collected in the
Children’s Hospital of SaarlandUniversity inHomburg/Saar. OPN levelsweremeasured by ELISA,
and statistical analysis was performed using SPSS software.
Results:Neonates, infants, toddlers, young children, adolescents, and adultswere divided into the
following six age groups: newborns (birth), infancy and toddlers (0-24 months), early childhood
(3-6 years), middle childhood (7-11 years), adolescence (12-18 years), and adults (> 18 years).
Highest blood OPN levels were found in the group of 0-1 years of age. OPN blood levels declined
significantly with age (Spearman r=−0.874; P< 0.001).
Conclusion:Ourwork is the first prospective and systematic study analyzingOPN cord blood and
bloodplasma levels in children of all ages. It is the first study yielding reference values for different
age groups from birth to young adulthood. Our data give insight on how OPN in umbilical cord
blood andOPN in blood plasma are physiologically influenced during childhood development and
growth with high OPN levels after birth and a constant age-related decline until the age of 14,
whenOPN levels reach similar values to thosemeasured in adults.
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1 INTRODUCTION
For the establishment of diagnostic or prognostic biomarkers, refer-
ence ranges need to be established. New proteins gain more attention
as biomarkers in monitoring different cancer types.1,2 Osteopontin
(OPN), a multifunctional glycosiliaoprotein, is involved in several phys-
iological processes such as bone formation, angiogenesis, apoptosis,
inflammation, biomineralization, cell viability, and immune response.3,4
Abbreviations: BALB, bone alkaline phosphatase; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked Immunosorbent Assay; OPN, osteopontin; PDA, patent ductus arteriosus; PINP,
procollagen type I; s-CTX, serumC-telopeptide of type I collagen.
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OPN acts on organisms by playing a key role in secretion levels of
interleukin-10, interleukin-12, interleukin-3, interferon-𝛾 , integrin
𝛼vB3, nuclear factor kappa, macrophage, and T cells, regulating the
osteoclast function and affecting CD44 receptors.5,6
First described 1979 by Senger et al.,7 numerous studies were
published with OPN being investigated in blood and tissue of patients
with cancer and noncancer diseases.8,9 OPN is often described as an
oncogene or cancer metastasis gene having a high potential as an
Pediatr Blood Cancer. 2020;67:e28272. wileyonlinelibrary.com/journal/pbc 1 of 8
https://doi.org/10.1002/pbc.28272
2 of 8 NOURKAMI-TUTDIBI ET AL.
independent prognostic blood biomarker in various types of
cancers.10,11 Studies comparing OPN in children with and without
cancer are very sparse.12-17 AsOPN is also a Th2 inflammation-related
protein, some studies analyzed the expression of OPN and corre-
lation of OPN to other cytokines in pediatric patients with allergic
rhinitis.18-20 A recently conducted study measured OPN levels in
pediatric patients with traumatic brain injuries. Here OPN in blood
plasma might have a prognostic and predictive value on pediatric
patients with traumatic brain injuries.21 However, the potential of
OPN as a biomarker in pediatric cancer patients is well accepted.22
A systematic study of reference values for OPN from the new-
born through the adult age is still lacking. Besides gender and age, fac-
tors during childhood development are well known to influence blood
parameters.23 Biomarkers and laboratory values in children are sub-
ject to age-specific variability.24
The availability of age-specific reference values is indispensable for
a valid interpretation of the results of laboratory tests in children,
since many biomarkers vary during the physiological development of
a healthy child.25-27 Most of the challenges encountered when estab-
lishing pediatric reference values are related to a growing anddevelop-
ing immune system that influences concentrations of various analytes
routinely measured in clinical diagnostic laboratory.28-30 Differences
in physical size, organmaturity, blood fluid compartments, immune and
hormone responsiveness, nutrition, andmetabolism are likely to affect
normal analyte concentrations, such as biomarkers, in children.31,32
Besides this, pediatricians try to limit blood tests to a minimum due
to the smaller body blood volume and the often-traumatic experience
for children. Hence, clinical investigations for reference values in a
pediatric setting are sparse and often done when blood for diagnostic
workup has to be taken anyhow. Establishing pediatric reference val-
ues for new or existing biomarkers is challenging and requires a more
complex approach as theremight be significant differences within var-
ious age groups over childhood development.33
The aim of this study was to establish reference values for OPN
in umbilical cord blood of term neonates and blood plasma of infants,
children, adolescents, and adults. In addition, we wanted to evalu-
ate whether gender or body mass index (BMI; calculated as weight
(kg)/[height (m)]2) influences OPN blood plasma levels.
2 METHODS
2.1 Sample collection and laboratorymethods
This trial followed the tenets of the Declaration of Helsinki and was
approved by the local ethics committee (Ärztekammer des Saarlandes,
Germany, No.: 159/06). All probes were collected at the Children’s
Hospital of Saarland University Medical Center, Homburg/Saar,
Germany. In newborns the cord blood samples were drawn from
the umbilical cord vein immediately after birth. For ethical reasons,
as blood tests are often a traumatic experience for children, blood
samples were only collected in hospitalized children during routine
and necessary blood tests (Supporting Information Table S1 lists the
distribution of study participants according to diagnostic subgroups).
Inclusion criteria were the need for a venipuncture or intravenous
drip placement for diagnostic procedures or treatment. A total of 181
blood samples were collected and informed consent was obtained
upfront from parents for each blood sampling. Overall 37 newborns,
125 children, and 19 adults were included in the study. All blood
probes were taken into 1.3 mL K2-ethylenediaminetetraacetic acid
(EDTA) tubes (Sarstaedt, Nümbrecht, Germany) and stored at 8◦C.
Within 30 minutes after drawing, samples were centrifuged at 1000
× g for 10 minutes, and removed plasma was aliquoted and stored at
−80◦C until further use. The concentration of soluble OPN in plasma
was determined by the enzyme-linked immunosorbent assay method
(ELISA). We used the Human Osteopontin ELISA kit (product code
27158, Immuno-Biological Laboratories Co. Ltd, Gumma, Japan),
which has, according to our measurements, an inter-assay coefficient
of variation of 10.6% and an intra-assay coefficient of variation of
3.2%. To reduce analytical variation, all samples were measured in
duplicates, and results scatteringmore than 10%were reanalyzed.
2.2 Study participants and data collection
This is a cross-sectional study of neonates, children, adolescents,
and adults. Pediatric participants were consecutively enrolled while
attending at the Children’s Hospital of Saarland University, Homburg.
All neonates included in the study were healthy and term newborns
(gestational age≥37 completed weeks) with normal postnatal adapta-
tion delivered at the Department of Obstetrics and Gynecology, Uni-
versity of Saarland. Only newborns without any signs of maternal and
neonatal infectionwere included.Our adultswere voluntary studypar-
ticipants and healthy employees at the Children’s Hospital of Saarland.
To set up a representative reference collective of pediatric patients,
our probes have been sampled from children who had to have a blood
test for diagnostic workup.
Blood samples from in-house patients were collected after all
signs of infection were absent for at least 48 hours (C-reactive pro-
tein < 10 mg/dL, no rash or fever and clinical well-being). Here, blood
was sampled within last diagnostic workup upfront to same-day dis-
charge. Baseline characteristics such as age, gender, body weight, and
height were taken from the patient’s chart as well as all information
regarding principal and additional diagnosis, treatment plan, and sup-
plementary laboratory data.
A priori exclusion criteria of patients were defined on the basis
of diseases and conditions possibly influencing the synthesis or
regulation of OPN. These were cancer, metabolic, muscle, bone,
renal, cardiac, autoimmune, and allergic diseases. Prematurity, severe
acute infection, organ failure, and genetic syndromes have also been
excluded from the reference group. The following diagnoses were
accepted to be part of the reference group: state after cured infection,
benign and self-limiting abdominal pain, migraine, cerebral contusion,
coagulation defect, history of alcohol intoxication, benign epilepsy,
cognitive or speech developmental delay, minor surgical interventions,
diagnostic procedures (e.g., short stature workup, magnetic reso-
nance imaging, or endoscopy) and laboratory test results within the
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reference limits. In total, 117 individuals were included to final analy-
ses based on the above criteria (see Supporting Information Table S1).
To cover the different periods of human growth and development,
the reference group was divided into six subgroups: newborns (birth),
infancy and toddlers (0-24 months), early childhood (3-6 years), mid-
dle childhood (7-11 years), adolescence (12-18 years), and adults
(> 18 years).
2.3 Statistical analysis
Statistical analysis was performed using SPSS software, IBM SPSS
Statistics Version 20 for Windows (IBM Corporation, Armonk, NY).
All tests were two-sided. Differences with P < 0.05 were consid-
ered significant. Descriptive statistics for continuous variables were
expressed as the mean with standard deviation or medians with min-
imumandmaximum, and for categorical variables as absolute frequen-
cies with percentages using original untransformed values. Values of
OPN were analyzed for their normal distribution by the Kolmogorov-
Smirnov test and normal Q-Q plots. Natural logarithmic transforma-
tion of data was used for statistical analysis when needed. Differences
amongmore than two independent groups were analyzed by nonpara-
metric Kruskal-Wallis H test. Differences of OPN levels between two
independent groups were assessed by nonparametric Mann-Whitney
U test. In order to assess the relationship between OPN plasma lev-
els and age in the reference group, Pearson correlation coefficient was
determined. The association between height, weight, BMI, body sur-
face area, and OPN plasma concentrations were tested by partial cor-
relation while controlling for the effect of age. After verification of
normal distribution and exclusion of outliners by applying the Tukey
method, we derived OPN reference intervals by nonparametric meth-
ods and datawere presented asmedianwith 2.5th to 97.5th percentile
ranges. Smoothed reference curves ofOPN levelswere constructed by
theLambda-Mu-Sigma (LMS)methodofCole andGreen, using theLMS
Chartmaker Light version 2.43 (Medical Research Council, UK).34
3 RESULTS
3.1 Characteristics of participants
Blood samples of 117 patients were included (53.4% male and 46.6%
female). Table 1 summarizes the distribution by age group and gender.
Except for adults, gender was equally distributed over all age groups
(P < 0.08). The participants’ median age was 6.6 (0.0-50.9) years and
was not normally distributed (P < 0.001). There was no significant
age difference between male versus female participants (children: 4.1
(0-18.9) years, P< 0.68 and adults: 30 (21.1-50.9) years, P< 0.23).
In total, 36 healthy newborns were included in the study. All new-
borns had normal Apgar scores at five minutes and normal umbili-
cal artery pH (perinatal characteristics of newborns are presented in
Supporting Information Table S2). The OPN values were normally dis-
tributed (P < 0.20). Mean OPN blood plasma level in cord blood was
2300 ± 552 ng/mL. No significant association was seen between OPN
TABLE 1 Distribution and age of participants by age group and
gender
Male Female
n (%) n (%) Total
Participants Age group Age Age P
a


































Total 63 (53.4%) 54 (46.6%) 117
Data are given as absolute frequencies with percentages, n (%).
aTested byMann-Whitney test, significant for P< 0.05.
bGestational age in completed weeks as median with minimum and maxi-
mum.
cAge is given in years as median withminimum andmaximum.
values and gender or any other perinatal parameters (mode of delivery,
gestational age, Apgar score at fiveminutes, umbilical artery blood pH,
birth weight, and fetal growth).
To determine possible differences in plasma OPN level, diagnostic
subgroups within the included children group (n = 63) were compared
by nonparametric Kruskal-Wallis analysis of variance. Diagnostic sub-
groups were not statistically different (P < 0.47) and were pooled
together as total reference group.
3.2 OPN blood plasma levels
OPN plasma concentrations did not show any association with
weight, height, BMI, and body surface area when tested by partial
correlation while controlling for the effect of age. Overall, we found
an age-dependent variation of OPN blood plasma levels and could
demonstrate that OPN in blood decreased significantly with growing
age irrespective of gender (Spearman r = −0.874; P < 0.001). Before
the calculation of reference values for OPN, the applied Tukeymethod
identified two outliers: Patient 1 (OPN level 1429 ng/mL) was a
10.2-year-old child with neurological signs and symptoms after cere-
bral contusion. Patient 2 (OPN level 160 ng/mL) was a 12.0-year-old
female with known von Willebrand factor syndrome and congenital
cholesteatoma, who underwent mastoidectomy. Figure 1 shows the
distribution of OPN blood levels according to age groups. OPN plasma
level differed significantly between all six age groups (P from < 0.001
to 0.002) except for toddlers versus early childhood, middle versus
early childhood and adolescence versus middle childhood.
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F IGURE 1 Distribution of OPN plasma levels according to age groups. Box plots represent interquartile range, whiskers the range, and
horizontal lines represent themedian; *Significant at P< 0.0033 (0.05/15) tested byMann-WhitneyU test
F IGURE 2 Reference ranges for OPN level in children and adults
As no differencewas found between plasmaOPN levels ofmale and
female participants of all age groups, both genders were combined for
the calculation of percentiles. LMS analysis revealed smoothed refer-
ence curves of OPN levels as shown in Figure 2. OPN values progres-
sively decreasedwith age, particularly during infancy and toddlerhood.
The percentile curve showed a great variance at birth with narrowing
reference ranges toward adulthood.
4 DISCUSSION
Here we report reference values for OPN measured in the umbilical
cord blood of term neonates and blood plasma of infants, children,
adolescents, and adults. This is the first study prospectively estab-
lishing reference values for OPN in a pediatric setting from birth to
20 years of age. Our data show that OPN is independent of gender
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and BMI groups. We were able to demonstrate that OPN values
in blood plasma are age dependent. One major finding of this trial
is that OPN levels reach a maximum in umbilical cord blood and
during the neonatal period of healthy term babies. In addition, our
data show a significant and constant decline of OPN blood plasma
levels over all age groups beyond the age of one year. We could
demonstrate that OPN blood plasma levels decrease with age until
they reach similar values to those measured in adults after the age of
14 years.35,36
The neonatal/postnatal peak of OPN expression may be due to an
increased bone turnover.37,38 Joung et al. showed that OPN in cord
blood is significantly higher than in adults.39 As they did not inves-
tigate children of other age groups, they were not able to discrimi-
nate between the rise and decline of OPN after newborn period, but
they were able to show that there is an inverse correlation between
OPN and gestational age. In the preterm cohort, theywere also able to
demonstrate that patent ductus arteriosus was independently associ-
ated with higher OPN values.40 This is not surprising, as recently pub-
lished data once again indicated OPN and its potential role in cardiac
disease.41,42
Other markers for bone turnover such as osteocalcin and procolla-
gen type I show a similar peak of OPN within the first year of life.43
In contrast, markers such as serum C-telopeptide of type I collagen
andbone alkaline phosphatase showpeak values during and a constant
decline after puberty.44 AlthoughOPNplays an important role in bone
turnover, an increase according to pubertal stage could not be seen
within our data.
Age-related declines of biomarkers are a typical phenomenon
during childhood, as demonstrated by Caselli et al. for adiponectin
and brain natriuretic peptite.45 In addition, many other studies
establishing reference values in a pediatric setting observed inter-
esting patterns for several analytes, proteins, or blood components
in newborns, including high levels during the neonatal period.26
These circumstances might be due to adaptational processes in the
early neonatal period. For many years, the CALIPER program of the
University of Toronto, Sick Kids Hospital, investigates the influence
and interpretation of laboratory values in children. The CALIPER pro-
gram is a national research initiative addressing pediatric reference
values28-30
Studies analyzing OPN in a pediatric setting of nonmalignant dis-
eases matching healthy controls are very sparse. Only a few stud-
ies have been published in the past.14,15 Two studies measured
OPN in healthy cohorts for baseline assessment reflecting one age
group without covering children of other age groups.39,46 Our study
is the first to cover all age groups, from birth to young adults.
OPN in serum yields lower values than those of plasma samples,
as OPN is cleaved by thrombin after blood coagulation. Serum and
plasma OPN though is highly correlated to each other,47 accord-
ing to Lanteri et al., plasma values are 3.8- to 4.8-fold higher than
serum.48
Al-Ayadhi et al. measured a mean serum OPN level of 122.3 ±
39.2 ng/mL in 42 healthy subjects with amean age of 7.7± 2.5 years.16
When multiplying these values with a factor of 3.8 or 4.8, a mean
OPN value of 463.7 ng/mL or 587.0 ng/mLwould be the concentration
in plasma, respectively. These values are in good correlation with
our mean values evaluated for children between 1 and 14 years of
age. On the contrary, significantly lower OPN values were found in
healthy controls within the two studies conducted by Honsawek et al.
Numbers of controls were low in both studies, though with 10 and
13 children, respectively, and a mean age of 7.4 ± 3.9 and 8.3 ± 1.1
years.49,50 Akalema et al. analyzed OPN serum levels in children with
asthma disease and 42 healthy controls with a mean age of 3.0 ±
1.9 years, measuring far lower OPN values in the cohort of healthy
controls than those reported in our cohort.51 These might be due
to the use of different OPN assays as well as the fact that OPN was
measured in serum and not in blood plasma. The data may be biased,
even though when adjusting values from sera to blood plasma as
recommended by Lanteri et al.
There are a few studies measuring OPN levels in pediatric patients
with type I diabetes mellitus (T1DM). Saki et al. analyzed serum OPN
levels in a large cohort of patients with T1DM including 87 healthy
sex- and age-matched controls. The mean age in healthy controls was
12.6± 5.6 years, and meanOPN levels were 13.8 ng/mL,52 correlating
with OPN values in the blood plasma of 52.5 or 66.3 ng/mL, respec-
tively, when multiplying with 3.8 or 4.8. Values are by far lower than
those measured in healthy children of the corresponding age group in
our study. Here, the use of different assays might be one cause; differ-
ent ethnicity of study cohorts has to be kept in mind as well. Another
study analyzed data in T1DM patients and matched healthy con-
trols in sera that were 10-fold higher and more comparable with our
results.53
Talat et al. also measured serum OPN levels in T1DM patients
including 60 healthy age-matched controls. Themean age in their con-
trol group was 12.0 ± 2.2 years, and mean OPN levels were 89 ±
29 ng/mL.54 These values correlate with plasma OPN levels of 338.2
± 110.2 ng/mL and 427.2 ± 140 ng/mL, respectively, and are in good
accord with our OPN values of the same age group. Abo El-Asrar
et al. measured serumOPN levels in patients with T1DM andmatched
healthy controls,which are also in goodaccordwithour data. Themean
age of the control group (n = 40) was 12.1 ± 2.9 years with mean OPN
values of 90 (50-120) ng/mL. According to Lanteri et al., the OPN val-
ues in plasma should then be 342 (190-456) or 432 (240-576) ng/mL,
respectively. These values are comparable with our values in healthy
children, although El-Asrar et al. did not divide the cohort of controls
with a range of 6-17 years into smaller age groups.55
A large study conducted by Schreier et al. analyzed OPN levels in
tissue and serum samples of lean and obese children. The authorswere
able to demonstrate that OPN is a BMI independently related marker
of early endothelial dysfunction on children.56 The median OPN levels
in lean, healthy children were 135 ng/mL. According to Lanteri et al.,
these values correspond to 513 or 648 ng/mL, respectively (mean age
12.9± 2.9 years), and are in good accordwith our data. Schreiber et al.,
though, demonstratedanelevationofOPNduringpuberty,which is not
supported by our data.
Table 2 provides an overview of OPN levels measured in umbilical
cord blood, serum, and blood plasma of research studies conducted
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collective (n) Age (years)
OPN value
(ng/mL)














2017 Saki52 Type I diabetes
mellitus
Serum 87 12.6± 5.3 13.8± 6.3 87 12.0± 4.4 14.2± 7.4
2016 Talat54 Type I diabetes
mellitus
Serum 60 12± 2.2 89± 29 60 11.8± 2.2 130.7± 30.4
2016 Schreier56 Lean healthy
children vs
obese children
Serum 65 12.9± 2.9 135 (75-175)a 87 11.8± 2.0 125 (75-150)a










15 >3 years 42 (29-54) 42 >3 years MS−: 56 (23-78)
SS: 59 (31-79)






372± 109 114 35-36weeks 467± 149
2013 Karamizade53 Type I diabetes
mellitus




87 m: 8.2± 3.9
f: 9.1± 3.2
49.0± 22.3 (m+ f)






Plasma 21 11.5 4.3 (1.0-16.0) 51 11.5 6.8 (1.8-41.4)
2011 Al-Ayadhi16 Autism Serum 42 7.8± 2.5 122.3± 39.2 42 7.8± 2.5 197.1± 48.8
2011 Honsawek50 Biliary atresia Plasma 13 8.3± 1.1 27.5± 6.4 59 8.2± 0.4 146.9± 19.1
2010 Honsawek49 Liver fibrosis and
biliary atresia
Plasma 10 7.4± 3.9 15.1± 15.0 30 7.2± 3.4 47.0± 56.4
Values are given asmean± standard deviation or median (25th-75th percentiles).
aValues are derived from boxplot; m=male and f= female; n.a.= not applicable.
in a pediatric setting of different types of diseases within the last
decade. Most of the studies listed below do have small cohorts of
healthy controls. Some do have higher numbers of healthy controls,
but none analyzed OPN values in a pediatric setting, including all
age groups. Studies that analyzed OPN values in cerebrospinal fluid,
urine, tear, and/or tissue samples are not listed below. Only studies
with healthy controls and data about patient’s age are presented in
Table 2.
Finally,we alsomeasuredOPN levels in 19healthy adult volunteers.
The mean OPN level was 330 ng/mL, which shows good correlation
with published literature.35,36
Our study has several limitations. First, we did not use blood sam-
ples from healthy nonhospitalized children, as blood sampling is most
often associatedwith a traumatic experience for children. This is a cur-
rent and constant problem faced when trying to establish reference
values for pediatric patients. Pediatric values have always been most
challenging.
For that purpose, many laboratories use an entire hospitalized pop-
ulation and remove outliers to establish reference values.57 Therefore,
pediatric cohorts and reference values often vary from laboratory to
laboratory.58
5 CONCLUSION
Our study is the first systematic analysis, setting up reference values
for OPN over all age groups within a pediatric setting with cord blood
of term neonates and blood plasma in infants, toddler, young children,
adolescents, and adults.We could clearly demonstrate thatOPNblood
plasma levels are significantly age dependent and not related to any
other variables such as gender, weight, or BMI. We need further stud-
ies with a larger number of patients to verify our data. In addition, to
clarify the role of OPN in the blood plasma of children with different
cancer types, further investigations are needed.
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